A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Conditions:   Advanced Solid Tumors;   Advanced or Metastatic Gastric Cancer;   Advanced or Metastatic Gastroesophageal Junction Cancer Intervention:   Drug: MRG002 Sponsor:   Shanghai Miracogen Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials